CR-CSSS Champlain-Charles-Le Moyne
Quick facts
Marketed products
- aflibercept + FOLFIRI · Oncology
Aflibercept blocks VEGF signaling to inhibit tumor angiogenesis, while FOLFIRI chemotherapy directly kills cancer cells through fluorouracil and irinotecan. - Piperacillin-tazobactam administered in a standard infusion
Phase 3 pipeline
- Emend® (Aprepitant) · Oncology
Aprepitant blocks substance P neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting. - Zyprexa® (OLANZapine 5MG) · Psychiatry
Zyprexa works by blocking the action of dopamine and serotonin in the brain, which helps to reduce symptoms of psychosis.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: